• 1
    Jelfs P, Coates M, Giles G et al. Cancer in Australia 1989–90 (with projection to 1995). Cancer Series no. 5. Canberra: Australian Institute of Health and Welfare, 1996
  • 2
    Giles G, Thursfield V, Staples M. The bottom line: trends in cancer mortality, Australia 1950–91. Cancer Forum 1994; 18: 12 23
  • 3
    Buck CA. Prostate cancer question and answers. 1st edn, Chapt 1. Merit Publishing International, 1995: 10 9
  • 4
    Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8 30
  • 5
    Mettlin C, Jones G, Averett H et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup. Prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42 6
  • 6
    American Urological Association Policy Statement. Early detection of prostate cancer and use of transrectal ultrasound. 1992 Policy Statement Book. Baltimore: American Urological Association, 1992: 4.20
  • 7
    Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815 6
  • 8
    Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215 20
  • 9
    Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860 4
  • 10
    Christensson A, Bjork T, Nilsson O et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100
  • 11
    Hanley JA & McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839 43
  • 12
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991; 324: 1156 61
  • 13
    Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841 5
  • 14
    Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of prostate gland. Arch Surg 1941; 43: 209
  • 15
    Gleave ME, Hsieh JT, Wu HC, Eschenbach AC, Chung LWK. Serum prostatic specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor, and endocrine and growth factors. Cancer Res 1992; 52: 1598 605
  • 16
    Lee C, Sutkowski DM, Sensibar JA et al. Regulation of proliferation and production of prostate-specific antigen in androgen sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995; 136: 796 802
  • 17
    Sasagawa I, Nakada T, Kubota Y, Sawamura T, Izumiya K. Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Int Urol Nephrol 1995; 27: 769 74
  • 18
    Kuhn JM, Billbaud T, Navratil H et al. Prevention of the transient adverse effects of a gonadotropin releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). NJ Med 1989; 321: 413
  • 19
    Takeuchi S, Yoshida K, Tosaka A, Kobayashi N, Uchijima Y, Saitoh H. Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer. Acta Urol Jap 1994; 40: 393 400
  • 20
    Wallace EM, Pye SD, Wild SR, Wu FC. Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. Int J Androl 1993; 16: 35 40
  • 21
    Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD et al. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol 1996; 156: 438 42
  • 22
    Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostatic specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214 20
  • 23
    Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostatic-specific antigen as a screening test for prostate cancer. Arch Intern Medicine 1993; 53: 2529 37
  • 24
    Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: critical issues for the practicing physician. Mayo Clin Proc 1994; 69: 59 68
  • 25
    Brawer MK, Bigler SA, Sohlberg OE et al. Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 1991; 38: 103 7
  • 26
    Mazzei T, Mini E, Eandi M et al. Pharmacokinetics, endocrine and antitumor effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose response evaluation. Drugs Exptl Clin Res 1989; 15: 373 87
  • 27
    Perren TJ, Clayton RN, Blackledge G et al. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother Pharmacol 1986; 18: 39 43
  • 28
    Aus G, Abrahamsson PA, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998; 159: 2013 6
  • 29
    Linde R, Doelle GC, Alexander N et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotrophin-releasing hormone agonist in normal men. N Engl J Med 1981; 305: 663 7